Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Cellceutix delighted with first results from Brilacidin dosing study

Monday, October 10, 2016 7:01
% of readers think this story is Fact. Add your two cents.

Cellceutix Corporation (OTC:CTIX) has reported a clinically meaningful improvement in four patients treated for inflammatory bowel problems with Brilacidin.

Six patients have been treated in the first cohort of the phase II study with the lowest dose, 50mg, and the results were from four of these patients.

Two achieved a 100% reduction in the symptoms and the other two 50%.

Brilacidin was generally well-tolerated and patients maintained stable normal vital signs during treatment, said Cellceut

In total, the phase II dosing study will comprise three cohorts (of six patients) suffering Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS) who will receive progressively escalating doses.

Arthur Bertolino, the company’s chief medical officer, said: “These results are extremely encouraging.

“We anticipate the anti-inflammatory properties of Brilacidin alone will lead to multiple beneficial applications of the drug candidate beyond its already demonstrated effect in antibacterial indications.”.

Leo Ehrlich, chief executive, added: “We are delighted to see such promising responses to treatment in the first group of patients given the lowest dose of Brilacidin.

“The immunomodulatory and anti-inflammatory properties are at the core of effectively treating many diseases and conditions, such as IBDs and oral mucositis.”  

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global

Top Alternative



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.